CORRECTING and REPLACING Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IN
Entering the clinic in the second half of 2024, KME-0584, an IRAK1/4/panFIt3 Inhibitor is a first in class investigational drug for relapsed/refractory AML and high-risk MDS patientsCINCINNATI--(BUSINESS WIRE)--Headline of release should read: Acute Myeloid Leukemia (instead of Acute Myeloid Lymphoma).The updated re...